Article Text

PDF

Viral hepatitis
PMO-169 Pegylated interferon α, Nitazoxanide, Telapravir, Ribavirin, in genotype 1 undergoing prior experienced chronic hepatitis C patients: a randomised placebo control clinical pilot trial (I N T R I G U E C) interim
  1. P Basu1,2,
  2. T Nair3,
  3. S Farhat3,
  4. M Jafri4,
  5. K Mittimani3,
  6. N James Shah3,
  7. L Ang3,
  8. S foustin3
  1. 1Department of Gastroenterology and Hepatology, Columbia University, College of Physicians and Surgeons, New York, New York, USA
  2. 2Gastroenterology, North Shore University, New York, USA
  3. 3Internal Medicine, North Shore University, New York, USA
  4. 4Internal Medicine, NYMC Richmond, New York, USA

Abstract

Introduction Chronic hepatitis C is a global challenge with end stage liver disease and rising Hepatocellular Carcinoma. Peg Interferon α and Ribavirin was the backbone of therapy. Recently introduced Directly Acting Antivirals -protease inhibitor has a promising role in escalating Sustained Viral Response in Response guided therapy in non-responders, partial and relapses. This study utilised Nitazoxanide (NTZ) and Telapravir, with SOC for 24 weeks in treatment experienced patients.

Methods 50 (n=50) patients were divided into Group A (n=12) NTZ 500 mg three times for 12 weeks, Group B (n=12) NTZ 500 mg twice daily for 24 weeks Group C (n=26) control. All received Peg Interferon α 2a 180 μg SQ QOW with fixed dose of Ribavirin 1200 mg daily for 24 weeks with Telapravir 750 mg three times daily for 12 weeks. Viral load was obtained at day 0, 7th day, 14th day, 4 weeks, 12th week and 24 weeks. Viral kinetics was analysed. In Group A: 5/12 (42%) Non-Responder, 6/12 (50%) partial responder, 2/12 (16%) relapsers. In Group B: 5/12 (42%) Non-responders, 6/12 (50%) partial responder, 1/12 relapsers (8%). In Group C: 10/26 (38%) non-responder, 10/26 (38%) partial responder, 4/26 (15%) relapsers, 2/26 (8%) unknown. Exclusion: Decompensated Cirrhotic, HCC, poor DM, Haemolytic Anaemia, Severe Coronary artery disease, major depression, renal failure, Prior severe skin rash, active drug and alcohol abuse. Side Effects: Anaemia 28/50 (56%), Neutropenia 14/50 (28%), Thrombocytopaenia 8/50 (16%), Fatigue 34/50 (68%), Depression 10/50 (20%), Mild skin rash 22/50 (44%), Severe skin rash 1/50 (2%). Use of Growth factors: Epogen 12/50 (24%) Neupogen 8/50 (16%) Elthrombopag 5/50 (10%).

ResultsGroup AGroup BGroup C
Undetectable9/12 (75%)10/12 (83%)16/26 (62%)
NR1/12 (8%)2/12 (16%)4/26 (15%)
PR1/12 (8%)12/12 (100%)3/26 (11%)
AVR11/12 (92%)12/12 (100%)20/26 (77%)
VRVR11/12 (92%)10/12 (83%)22/26 (84%)
RVR9/12 (75%)10/12 (83%)18/26 (70%)
EVR9/12 (75%)10/12 (83%)16/26 (62%)
ETVR9/12 (75%)10/12 (83%)16/26 (62%)

Conclusion This quadruple truncated regimen has excelled the RVR, ETVR over SOC with Directly Acting Antivirals over 13%, without any difference between 24 weeks of NTZ over 12. Needs a larger trial for validation.

Competing interests None declared.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.